← ANALYST RATINGS · TIPRANKS
Viatris (VTRS): analyst forecast and price target
Analyst consensus
Moderate Buy4 Buy3 Hold1 Sell
Ratings of 8 analysts in the last 3 months · top analysts only12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $20.00, the highest $26.00, the lowest $13.00. The average is +7.2% from the last price of $18.66.
Analyst ratings 16
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Glen Santangelo★★★★★★★★★★#2956 · hits 52% · avg +4.5% | Barclays | $22.00 | Buy | +17.9% | Reiterated | 15.10.26on TipRanks 05:07 | +4.2%next day +3.5% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $16.00 | Sell | −14.2% | Reiterated | 12.10.26on TipRanks 08:35 | −0.5%next day −1.6% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $13.00 | Hold | −30.3% | Reiterated | 12.10.26on TipRanks 06:55 | −0.5%next day −1.6% | ↗ |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $19.00 → $18.50−2.6% | Hold | −0.8% | Reiterated | 09.10.26on TipRanks Oct 8 22:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $19.00 → $18.50−2.6% | Hold | −0.8% | Reiterated | 09.10.26on TipRanks Oct 8 22:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $18.00 → $18.50+2.8% | Hold | −0.8% | Reiterated | 09.10.26on TipRanks Oct 8 22:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $19.50 | Buy | +4.5% | Upgrade | 09.10.26on TipRanks Oct 8 22:05 | — | |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $20.00 | Hold | +7.2% | Reiterated | 08.10.26on TipRanks Oct 9 08:10 | +0.1%next day +0.5% · 5 days +4.7% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $14.00 → $16.00+14.3% | Sell | −14.2% | Reiterated | 08.10.26on TipRanks Oct 9 04:55 | +0.1%next day +0.5% · 5 days +4.7% | ↗ |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $23.00 → $26.00+13.0% | Buy | +39.4% | Reiterated | 05.10.26on TipRanks 06:05 | −0.6%next day −1.0% · 5 days −0.9% | ↗ |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $19.00 → $18.50−2.6% | Hold | −0.8% | Reiterated | 05.10.26on TipRanks Oct 4 23:06 | — | |
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $17.00 → $19.00+11.8% | Hold | +1.8% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $17.00 → $19.00+11.8% | Hold | +1.8% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $17.00 → $19.00+11.8% | Hold | +1.8% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $16.50 → $18.00+9.1% | Hold | −3.5% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $17.50 → $19.50+11.4% | Hold | +4.5% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $19.00 | Hold | +1.8% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| Les Sulewski★★★★★★★★★★#1947 · hits 51% · avg +11.5% | Truist Financial | $25.00 | Buy | +34.0% | Initiated | 23.09.26on TipRanks 21:00 | +1.8%next day +1.8% · 5 days +0.6% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $12.00 → $13.00+8.3% | Hold | −30.3% | Reiterated | 16.09.26on TipRanks 07:10 | +2.7%next day −0.5% · 5 days −1.5% | ↗ |
| Daniel Clark★★★★★★★★★★#3492 · hits 65% · avg +17.4% | Leerink Partners | $20.00 | Buy | +7.2% | Initiated | 09.09.26on TipRanks 08:25 | −0.2%next day −0.1% · 5 days +4.2% | ↗ |
| Jasper Hellweg★★★★★★★★★★#2291 · hits 57% · avg +7.4% | Argus Research | $15.00 → $20.00+33.3% | Buy | +7.2% | Reiterated | 08.09.26on TipRanks 08:30 | −1.1%next day −0.2% · 5 days +1.4% | ↗ |
| Glen Santangelo★★★★★★★★★★#2956 · hits 52% · avg +4.5% | Barclays | $22.00 | Buy | +17.9% | Reiterated | 17.08.26on TipRanks Aug 18 05:25 | +0.5%next day +0.3% · 5 days +3.9% | ↗ |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $18.00 | Hold | −3.5% | Reiterated | 10.08.26on TipRanks 07:40 | −0.9%next day +0.3% · 5 days −0.3% | ↗ |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $23.00 | Buy | +23.3% | Reiterated | 07.08.26on TipRanks 07:21 | +0.2%next day −0.9% · 5 days −1.6% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $18.00 → $20.00+11.1% | Hold | +7.2% | Reiterated | 06.08.26on TipRanks Aug 7 08:35 | −7.5%next day +0.2% · 5 days −2.7% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $14.00 | Sell | −25.0% | Reiterated | 10.07.26on TipRanks 06:35 | −0.9%next day +1.5% · 5 days +7.8% | ↗ |
| Unknown Analyst | Jefferies | $17.00 | Buy | −8.9% | Reiterated | 20.03.26on TipRanks 09:25 | −0.8%next day −0.4% · 5 days +1.1% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Viatris
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $19.44 at a price of $17.72 (+9.7%); now: $20.00 at $18.66 (+7.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 6 | 4 | 3 | 3 | 5 | 6 |
| Hold | 5 | 4 | 5 | 4 | 4 | 5 |
| Sell | 0 | 0 | 1 | 1 | 1 | 2 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.64 (from $0.62 to $0.69). Last quarter: $0.69.
Sales
Next quarter’s sales estimate — $3.8B (from $3.7B to $3.9B). Last quarter: $3.8B.
Best top-analyst consensus in the sector · Healthcare
About Viatris
- CEO: Scott Andrew Smith
- Employees: 30,000
- Robert J. Coury Global Center, Canonsburg, PA, 15317, US
- www.viatris.com
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collabora
Data from the stock’s TipRanks forecast page, read 1 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗